THE TAPE

National Healthcare Corp.

$207.19▼ −0.36%
Last close
Relative strength
72RS
of 99, against every stock▼ -20 on the month
Cooling off
Unconfirmed
+5.4%
six months against the S&P 500
52-week range
−16.5%
from the high
$124.57$248.20
Setup
blue skyplayed out
−13.4%
against the pivot at $239.29
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +7% on a year ago
11/16 O 207.55 H 210.20 L 203.88 Vol 92.2K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS72
vs pivot−13.41%
Tightening1.16×
Dry-up0.82×
Up/down vol-0.09
From high17%
played out2 of 9checks
Previous breakout stopped out ▼ −9.96% in Apr
Cooling off
Support and resistance
Support below
$202.26
-2.4% · tested 5× · last 6 sessions ago
Resistance above
$215.05
+3.8% · tested 5× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 7.8 weeks and fell 11% from its ceiling at its deepest. The pivot is $239.29, and the stock closed 13.4% below it. Its relative strength rating is 72.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
-12.0%
Three months against the S&P 500
-8.2%
Six months against the S&P 500
+5.4%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Also on
Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap
45
days
Ex-dividend in 45 days
Dec 31, 2026
  1. Ex-dividendconfirmedin 45d
    Ex-dividend date
    Dec 31, 2026
How it moves on earnings

No past reports on record for this company yet.

The business
Revenue
$1.6B
+6.6% year on year
Operating margin
9.8%
Net margin
7.2%
Free cash flow
$221.8M
6.8% of market cap
Price to sales
2.05×
Price to earnings
28.3×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$408.0M
0.0% QoQ · +6.6% YoY
Gross margin
—
Net income
$13.6M
Positive
Free cash flow
$99.2M
Cash generating

What the numbers say

  • Revenue +6.6% year over year, -0.0% on the quarter
  • Good: Profitable: net income $14M, operating margin 10.0%
  • Good: Cash generating: operating cash flow $99M, free cash flow $99M
  • Net debt $435M · cash $67M
Revenue by quarter
Free cash flow
Net income
shares +1.9% in a year · net debt $435.3M
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-07
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Unusual volumeTape · 2026-11-07
5.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Earnings comingEvent · 2026-10-29
reports 2026-10-30
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
GappedTape · 2026-10-28
-5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-27
-5.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-09-19
12.9 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Should First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) Be on Your Investing Radar?Zacks Investment Research · 2026-10-08

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
1
$174,859 total
Sold on the open market
18
$8,548,182 total

Bought: Piercey Lisa. Sold: Dodson Vicki L, KIDD BRIAN F, McCreary Josh A, FLATT BEN ANDERSON SR, Gifford David R., Flatt Stephen Fowler, HASSAN EMIL E, LAROCHE RICHARD F JR.

Not counted above: 8 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-22 Dodson Vicki L · Sr.VP Patient Srvcssell4,834$1,087,650
2026-09-11 KIDD BRIAN F · SVP, CFOsell6,813$1,537,694
2026-09-10 McCreary Josh A · Senior VP & General Counselsell571$127,181
2026-09-10 McCreary Josh A · Senior VP & General Counselsell789$176,561
2026-09-10 McCreary Josh A · Senior VP & General Counselsell1,291$290,587
2026-09-10 McCreary Josh A · Senior VP & General Counselsell68$15,340
2026-08-28 FLATT BEN ANDERSON SR · Senior VP & CIOsell1,000$222,500
2026-08-25 FLATT BEN ANDERSON SR · Senior VP & CIOsell1,000$227,000

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

2 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
8w · 11%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
National Healthcare Corp. (NHC) — The Tape